FlandersBio on Twitter

Follow us on Twitter

regulatory - News

regulatory - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Galapagos receives transparency notification from Wellington Management Group LLP

23.12.2015

Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP. read more

“Industriële biotechnologie voor Europa : een geïntegreerde benadering”

13.11.2015

ERA-IB lanceert in samenwerking met ERASynBio en ERA-MBT de zevende gemeenschappelijke oproep voor multilaterale onderzoeksprojecten in industriële biotechnologie onder het motto : “Industriële biotechnologie voor Europa : een geïntegreerde benadering”. read more

Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA

13.11.2015

BONE THERAPEUTICS, (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces that its allogeneic bone cell therapy product, ALLOB®, received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of the genetic bone disorder osteogenesis imperfecta. read more

Esperite N.V. convenes EGM to approve new share option scheme

12.11.2015

Esperite N.V. (Euronext: ESP, 'Esperite') announces it is convening an extraordinary general meeting of Shareholders ("EGM") to be held on Wednesday 23 December 2015 to approve its new share option scheme. read more

ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)

12.11.2015

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of vitreo-retinal disorders, today announces that the FDA has accepted its Investigational New Drug (IND) Application for its CIRCLE study, a Phase II, randomized, double-masked, sham-controlled, multi-center study that will evaluate the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy (NPDR). read more

GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents

28.10.2015

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents. This follows an agreement signed between GSK and the Group in December 2013. read more

Transparency notification received from S.R.I.W. SA & Sofipôle SA

23.10.2015

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces it has received a notification of shareholding from S.R.I.W. SA & Sofipôle SA in accordance with the Belgian Law of 2 May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market. read more

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad

23.10.2015

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immune-oncology today announced the issuance of United States Patent No. 9,181,527 (“US Patent 9,181,527”) relating to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR). read more

TheraSolve Announces US Patent Issuance for MemoPatch®

15.09.2015

TheraSolve NV, a medication adherence innovator, announced today patent issuance from the United States Patent and Trademark Office for its innovative MemoPatch® reminder technology. Specifically designed to support patients with treatment compliance, MemoPatch® is a self-adhesive dermal patch that gives patients an automated, discreet yet clear stimulus on the skin when the next dose of medication is needed. MemoPatch® is currently patent protected in the US, EU, Japan, China and India. read more

Minister De Croo verwelkomt buitenlandse studenten bio-ingenieurswetenschappen UGent

08.09.2015

Minister van Ontwikkelingssamenwerking Alexander De Croo verwelkomt op 9 september 125 eerstejaarsstudenten uit meer dan zeventig verschillende landen die op 3 september met hun masteropleiding gestart zijn aan het International Training Centre (ITC) van de faculteit bio-ingenieurswetenschappen van de Universiteit Gent. Ze doen dat met een beurs die ze krijgen van VLir-UOS, het Interuniversitaire samenwerkingsverband rond ontwikkelingssamenwerking dat zijn middelen verkrijgt vanuit het Ministerie voor Ontwikkelingssamenwerking. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print